Saxagliptin inib Epub 2014 Mar 26

Epub 2014 Mar 26

NF-kappaB signaling blockade by Bay 11-7085 during early cardiac morphogenesis induces alterations of the outflow tract in chicken heart

WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib

In a SJSA xenograft model

Saxagliptin inib Epub 2014 Mar 26Saxagliptin, also known as BMS 477118, is a new oral hypoglycemic (anti diabetic drug) of the new dipeptidyl peptidase 4 (DPP 4) inhibitor class of drugs. Saxagliptin was approved in 2008 for the treatment of type 2 diabetes. Saxagliptin is a competitive DPP4 inhibitor that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose